Showing 21-30 of 5059 results for "".
- Phase 1 Study Begins for New Systemic for CPUOhttps://practicaldermatology.com/news/Phase-1-Study-Begins-New-Systemic-CPUO/2471095/The first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) anti-IL-31 biotherapeutic, Attovia Therapeutics announced. ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic co
- Evommune Initiates Phase 1 Study of EVO101 for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/evommune-initiates-phase-1-study-of-evo101-for-inflammatory-skin-diseases/2461117/Evommune, Inc. has enrolled the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being
- Review: GLP-1 Receptor Agonists May Benefit Both Psoriasis and Metabolic Diseasehttps://practicaldermatology.com/news/review-glp-1-receptor-agonists-may-benefit-both-psoriasis-and-metabolic-disease/2487389/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer additional benefits for patients with psoriasis, according to a new review and primer from the National Psoriasis Foundation Medical Board. The authors noted GLP-1 RAs have been associated with reductions in Psoriasis Area and
- FDA Approves Tapinarof Cream, 1%, for ADhttps://practicaldermatology.com/news/fda-approves-tapinarof-cream-1-ad/2470664/The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced. Organon received the FDA appr
- PD-1 Gene Variants Linked to Melanoma Riskhttps://practicaldermatology.com/news/pd-1-gene-variants-linked-melanoma-risk/2467088/A recent study has highlighted significant associations between specific single nucleotide variants (SNVs) in the PD-1 and PD-L1 genes and the risk of metastatic melanoma (MM). Researchers conducted the study at IRCCS Ospedale Policlinico San Martino in Genova, Italy, and included 125 patients wi
- FDA Accepts sNDA for Dermavant's Tapinarof Cream, 1%https://practicaldermatology.com/news/tapinarof-1-cream-progresses-toward-approval-pediatric-eczema/2462895/The U.S. Food and Drug Administration (FDA) has accepted Dermavant's Supplemental New Drug Application (sNDA) for tapinarof cream, 1% (VTAMA®), for the treatment of atopic dermatitis in (AD), according to a news release from the manufacturer. The FDA assigned a Prescription Drug User Fee
- GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areatahttps://practicaldermatology.com/news/glp-1-receptor-agonists-show-complex-evolving-role-in-alopecia-areata/2486415/The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meet
- Pediatric AD: Tapinarof Cream 1% Delivers Clear Skin and Reduced Burdenhttps://practicaldermatology.com/news/pediatric-ad-tapinarof-cream-1-delivers-clear-skin-and-reduced-burden/2484254/In the pivotal ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA, Organon) showed consistent and statistically significant efficacy across all pediatric age groups in children with atopic dermatitis (AD), with benefits extending to sleep and family impact o
- Study Explores Potential of GLP-1 Agonists for Skin Disease Managementhttps://practicaldermatology.com/news/study-explores-potential-glp-1-agonists-skin-disease-management/2468016/Recent research highlights the potential of GLP-1 agonists in managing dermatological conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease, especially in patients with obesity or type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (G
- Vtama Cream, 1% Continues to Wow in Scalp and Neck PsOhttps://practicaldermatology.com/news/vtama-cream-1-continues-to-wow-in-scalp-and-neck-pso/2462174/VTAMA (tapinarof) cream, 1% performed well in the treatment of psoriasis on the head and neck, according to its Phase 4, open-label trial. In the two 12-week Phase 3 pivotal studies (PSOARING 1 and 2; N=1025), VTAMA cream demonstrated a Physician Global Assessment (PGA) success rat